Acalabrutinib granted FDA Breakthrough Designation for MCL

09:29 EDT 2 Aug 2017 | CentreWatch

AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, announced that the FDA has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor in development for the […]

The post Acalabrutinib granted FDA Breakthrough Designation for MCL appeared first on CenterWatch News Online.

Original Article: Acalabrutinib granted FDA Breakthrough Designation for MCL


More From BioPortfolio on "Acalabrutinib granted FDA Breakthrough Designation for MCL"

Quick Search

Relevant Topics

AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...